By the same authors

Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study

Research output: Contribution to journalArticle

Author(s)

  • Shehzad Ali
  • Noman Paracha
  • Stuart Cook
  • Gavin Giovannoni
  • Giancarlo Comi
  • Kottil Rammohan
  • Peter Rieckmann
  • Per Soelberg Sørensen
  • Patrick Vermersch
  • Steven Greenberg
  • David A Scott
  • Alexandre Joyeux
  • CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group

Department/unit(s)

Publication details

JournalClinical drug investigation
DatePublished - 2012
Issue number1
Volume32
Number of pages13
Pages (from-to)15-27
Original languageEnglish

Abstract

Multiple sclerosis (MS) is a common, chronic, neurodegenerative condition associated with substantial healthcare and societal economic burden. Disease-modifying MS treatments have the potential to reduce health resource utilization (HRU), thereby reducing the attendant socioeconomic burden.

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations